NYSE:AZNAstraZeneca Stock Price, Forecast & News

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AZN stock has increased by 20.6% and is now trading at $53.76. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AstraZeneca.

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for AstraZeneca.

AstraZeneca plc (NYSE:AZN) announced its earnings results on Wednesday, April, 29th. The company reported $0.53 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.06. The company earned $6.35 billion during the quarter, compared to analysts' expectations of $5.95 billion. AstraZeneca had a net margin of 5.94% and a return on equity of 33.97%. The business's quarterly revenue was up 16.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.89 EPS. View AstraZeneca's earnings history.

AstraZeneca declared a semi-annual dividend on Tuesday, February 18th. Shareholders of record on Friday, February 28th will be paid a dividend of $0.95 per share on Monday, March 30th. This represents a yield of 2.8%. The ex-dividend date is Thursday, February 27th. View AstraZeneca's dividend history.

AstraZeneca's stock split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

11 Wall Street analysts have issued 12 month price targets for AstraZeneca's shares. Their forecasts range from $60.00 to $65.00. On average, they expect AstraZeneca's share price to reach $61.67 in the next year. This suggests a possible upside of 14.7% from the stock's current price. View analysts' price targets for AstraZeneca.

News articles about AZN stock have trended very negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. AstraZeneca earned a news impact score of -3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about AstraZeneca.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Novartis (NVS), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Vertex Pharmaceuticals (VRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), AbbVie (ABBV), AT&T (T), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Cisco Systems (CSCO), Bank of America (BAC) and Johnson & Johnson (JNJ).

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca's stock is owned by many different retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.01%), Vigilant Capital Management LLC (0.01%), Park National Corp OH (0.01%), Town & Country Bank & Trust CO dba First Bankers Trust CO (0.00%), Mount Yale Investment Advisors LLC (0.00%) and Gradient Investments LLC (0.00%). View institutional ownership trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Gradient Investments LLC, Park National Corp OH, Mount Yale Investment Advisors LLC, Private Trust Co. NA, Town & Country Bank & Trust CO dba First Bankers Trust CO, and Courier Capital LLC. View insider buying and selling activity for AstraZeneca.

AZN stock was purchased by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Fulton Breakefield Broenniman LLC, Vigilant Capital Management LLC, Envestnet Asset Management Inc., Ellevest Inc., Carroll Financial Associates Inc., First Financial Bank Trust Division, and Patriot Financial Group Insurance Agency LLC. View insider buying and selling activity for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $53.76.

AstraZeneca has a market capitalization of $141.09 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.

The official website for AstraZeneca is www.astrazeneca.com.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]